These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 5677210)
41. [Influence of 3,5-dimethylisoxazol short-term administration on the carbohydrate metabolism in elderly diabetics with secondary failure of sulfonylurea treatment]. Geyer G; Sokopp B Wien Klin Wochenschr; 1969 Oct; 81(40):701-5. PubMed ID: 5344305 [No Abstract] [Full Text] [Related]
42. Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in a cross-over study in diabetics not controlled by diet alone. Sönksen PH; Lowy C; Perkins JR; West TE Diabetologia; 1981; 20(1):22-30. PubMed ID: 6781962 [No Abstract] [Full Text] [Related]
43. The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal. Tsalikian E; Dunphy TW; Bohannon NV; Lorenzi M; Gerich JE; Forsham PH; Kane JP; Karam JH Diabetes; 1977 Apr; 26(4):314-21. PubMed ID: 849812 [TBL] [Abstract][Full Text] [Related]
44. Effect of refeeding after starvation on basal and tolbutamide-stimulated insulin secretion and beta-adrenergic receptor function in the regulation of insulin release and lipolysis in obese patients. Dobrohorska H; Sulima D; Oskaldowicz K; Gruszczyńska M; Gołebiowska I Acta Physiol Pol; 1981; 32(6):703-12. PubMed ID: 6293250 [TBL] [Abstract][Full Text] [Related]
45. [Evaluation of therapy of diabetes mellitus, with special reference to the control of diabetes mellitus with oral antidiabetics]. Kadota I Nihon Rinsho; 1969 Aug; 27(8):2136-50. PubMed ID: 4901777 [No Abstract] [Full Text] [Related]
46. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Fajans SS; Brown MB Diabetes Care; 1993 Sep; 16(9):1254-61. PubMed ID: 8404429 [TBL] [Abstract][Full Text] [Related]
47. Plasma hydroxycorticosteroids circadian rhythm in diabetic adult subjects under different types of treatment. Serio M; Della Corte M; Piolanti P; Romano S; Giglioli L; Giusti G Ann Endocrinol (Paris); 1971; 32(3):403-8. PubMed ID: 5114905 [No Abstract] [Full Text] [Related]
48. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899 [TBL] [Abstract][Full Text] [Related]
49. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877 [TBL] [Abstract][Full Text] [Related]
50. [Evidence of a reduction of insulin secretion in diabetes with or without obesity. Discussion of the therapeutic use of biguanides]. Luyckx A; Lefebvre P Ann Endocrinol (Paris); 1969; 30(6):717-30. PubMed ID: 5384987 [No Abstract] [Full Text] [Related]
51. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093 [TBL] [Abstract][Full Text] [Related]
52. [Chlorpropamide-metformin in obese diabetic patients or with secondary response failure to sulfonylureas]. Garcia Viveros M; Lozano Castañeda O; Quibrera Infante R; Rull JA Prensa Med Mex; 1969; 34(9):391-6. PubMed ID: 5378265 [No Abstract] [Full Text] [Related]
53. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R; Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659 [TBL] [Abstract][Full Text] [Related]
55. [What is reliable in the therapy of diabetes mellitus?]. Sauer H; Böninger C Internist (Berl); 1970 Dec; 11(12):430-6. PubMed ID: 4924814 [No Abstract] [Full Text] [Related]
56. Combinations of oral hypoglycemic drugs in obese, insulin-resistant diabetics. Fineberg SK Geriatrics; 1968 Sep; 23(9):137-46. PubMed ID: 5673663 [No Abstract] [Full Text] [Related]
57. Oral treatment of diabetes mellitus. Chhetri MK J Indian Med Assoc; 1968 May; 50(10):486-8. PubMed ID: 4883853 [No Abstract] [Full Text] [Related]
58. Physiological and clinical aspects of circadian variations in glucose tolerance. Wojtczak-Jaroszowa J Chronobiologia; 1977; 4(4):363-84. PubMed ID: 350522 [TBL] [Abstract][Full Text] [Related]
59. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Nyholm B; Walker M; Gravholt CH; Shearing PA; Sturis J; Alberti KG; Holst JJ; Schmitz O Diabetologia; 1999 Nov; 42(11):1314-23. PubMed ID: 10550415 [TBL] [Abstract][Full Text] [Related]
60. Effects of metformin on plasma glucose, insulin, FFA, glucagon, growth hormone and cortisol responses to oral glucose in subjects with chemical diabetes. Giugliano D; Torella R; Improta L; Scognamiglio G Farmaco Prat; 1979 Jan; 34(1):32-41. PubMed ID: 378687 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]